Last reviewed · How we verify
Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
Rituximab, Gemcitabine, Oxaliplatin, Dexametasone is a Small molecule drug developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea. It is currently in Phase 2 development.
At a glance
| Generic name | Rituximab, Gemcitabine, Oxaliplatin, Dexametasone |
|---|---|
| Sponsor | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab, Gemcitabine, Oxaliplatin, Dexametasone CI brief — competitive landscape report
- Rituximab, Gemcitabine, Oxaliplatin, Dexametasone updates RSS · CI watch RSS
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea portfolio CI
Frequently asked questions about Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
What is Rituximab, Gemcitabine, Oxaliplatin, Dexametasone?
Rituximab, Gemcitabine, Oxaliplatin, Dexametasone is a Small molecule drug developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea.
Who makes Rituximab, Gemcitabine, Oxaliplatin, Dexametasone?
Rituximab, Gemcitabine, Oxaliplatin, Dexametasone is developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (see full Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea pipeline at /company/grupo-espa-ol-de-linfomas-y-transplante-aut-logo-de-m-dula-sea).
What development phase is Rituximab, Gemcitabine, Oxaliplatin, Dexametasone in?
Rituximab, Gemcitabine, Oxaliplatin, Dexametasone is in Phase 2.